Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

Science

Volumn 272, Issue 5265, 1996, Pages 1167-1170

  Mellors, John W ^a,b,c   Rinaldo Jr , Charles R ^a,b   Gupta, Phalguni ^b   White, Roseanne M ^d   Todd, John A ^d   Kingsley, Lawrence A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; VIREMIA;

EID: 0030070991     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.272.5265.1167     Document Type: Article

References (31)

1. A. Muñoz et al., Am. J. Epidemiol. 130, 530 (1989).
2. A. Muñoz et al., J. AIDS Hum. Retrovir. 8, 496 (1995).
3. C. M. Tsoukas and N. F. Bernard, Clin. Microbiol. Rev. 7, 14 (1994).
4. J. L. Fahey et al., N. Engl. J. Med. 322, 166 (1990).
5. K. Saksela, C. Stevens, P. Rubinstein, P. E. Taylor, D. Baltimore, Ann. Intern. Med. 123, 641 (1995).
6. E. Hogervorst et al., J. Infect Dis. 171, 811 (1995).
7. J. W. Mellors et al., Ann. Intern. Med. 122, 573 (1995); S. Jurrians et al., Virology 204, 223 (1994); D. R. Henrard et al., JAMA 274, 554 (1995).
8. J. W. Mellors et al., Ann. Intern. Med. 122, 573 (1995); S. Jurrians et al., Virology 204, 223 (1994); D. R. Henrard et al., JAMA 274, 554 (1995).
9. J. W. Mellors et al., Ann. Intern. Med. 122, 573 (1995); S. Jurrians et al., Virology 204, 223 (1994); D. R. Henrard et al., JAMA 274, 554 (1995).
10. Details of the recruitment and characteristics of the MACS cohort have been described elsewhere (9). The MACS protocol was approved by the Biomedical Institutional Review Board of the University of Pittsburgh. All subjects gave written informed consent after the potential consequences of study participation were explained.
11. R. A. Kaslow et al., Am. J. Epidemiol. 126, 310 (1987).
12. + T cells by the total lymphocyte count.
13. J. Giorgi et al., Clin. Immunol. Immunopathol. 55, 173 (1990).
14. For subjects developing AIDS, the samples tested were from study entry, the first follow-up visit (6 months), the most recent visit before AIDS diagnosis, and equally spaced visits in between. For AIDS-free subjects, the samples tested were from study entry, the 6-month follow-up visit, the last available visit, and equally spaced visits in between.
15. Developed by Chiron, the assay measures HIV-1 RNA associated with viral particles that are separated from 1.0-ml plasma samples by centrifugation at 23,500g for 1 hour at 4°C. Performance characteristics of the assay have been described elsewhere (14). For our study, the interassay coefficient of variation for the positive control samples tested with each batch of experimental samples was 18%. All samples were coded and the assay operators were blinded to clinical outcomes.
16. J. Todd et al., J. AIDS Human Retrovir. 10, S35 (1995).
17. E. L. Kaplan and P. Meier, J. Am. Stat Assoc. 53, 457 (1958). Kaplan-Meier analyses were performed with Statistica version 4.5 (StatSoft, Tulsa, OK).
18. D. R. Cox and D. Oakes, Analysis of Survival Data (Chapman & Hall, London, 1984). Cox proportional hazards analyses were performed with Splus version 3.3 (StatSci Division of Mathsoft, Seattle, WA).
19. B. J. Kennedy et al., Cancer 56, 2547 (1985).
20. K. W. Falterman et al., ibid. 34, 951 (1974).
21. D. D. Ho, T. Moudgil, M. Alam, N. Engl. J. Med. 321, 1621 (1989); R. W. Coombs et al., ibid., p. 1626; P. Gupta et al., Virology 196, 586 (1993).
22. D. D. Ho, T. Moudgil, M. Alam, N. Engl. J. Med. 321, 1621 (1989); R. W. Coombs et al., ibid., p. 1626; P. Gupta et al., Virology 196, 586 (1993).
23. D. D. Ho, T. Moudgil, M. Alam, N. Engl. J. Med. 321, 1621 (1989); R. W. Coombs et al., ibid., p. 1626; P. Gupta et al., Virology 196, 586 (1993).
24. X. Wei et al., Nature 373, 117 (1995).
25. D. D. Ho et al., ibid., p. 123.
26. A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, Science 271, 1582 (1996).
27. W. A O'Brien et al., N. Engl. J. Med. 334, 426 (1996).
28. W. Freimulh et al., paper presented at the Third Conference on Retroviruses and Opportunistic Infections (Infectious Disease Society of America), Washington, DC, 28 February to 1 March 1996;
29. S. Hammer et al., ibid.
30. V. DeGruttola, R. Gelman, S. Lagakos, in AIDS Clinical Trials, D. Finkelstein and D. A. Shoenfeld, Eds. (Wiley, New York, 1995), pp. 129-142.
31. We thank the participants and staff of the Pitt Men's Study for their dedication and support. Supported by Public Health Service contract N01-Al-72632 and cooperative agreement U01-Al-35041 and by grant support from the National Institutes of Health (R01 Al34301-01 and Al34294-01A2), the Medical Research Service of the Department of Veterans Affairs, and the Pathology Education and Research Foundation of the University of Pittsburgh.